ALK and non-small cell lung carcinoma: Targeted therapies using tyrosine kinase inhibitors (TKIs) have shown efficacy against ALK-positive cancers, with crizotinib being the first TKI approved by the U.S. Food and Drug Administration (FDA) for NSCLC.